Dr. KSS MD PhD

Author Bio

Dr. KSS MD PhD
I am an MD with an additional PhD in biochemistry, and for the past 20 years, in addition to practicing, being a researcher, and conducting clinical trials, I have been investing in biotech companies. I earned my degrees at a top 10 US institution, where I was an NIH scholar and graduated with top honors. I have extensive post-doctoral research experience and am board certified in internal medicine and gastroenterology. I am a member of Phi Beta Kappa and Alpha Omega Alpha (academic honor societies, the latter in medicine) and am a Fellow of the American College of Physicians, the American equivalent of being FRCP in certain Anglophone countries. My hobbies are traveling (I have been to 100 countries), chamber music, literature, film and Asian pottery. My goal as a Stock Gumshoe contributor is to discuss companies and use discussions of their technology, their drugs or planned drugs, as ways of teaching about physiology and disease states, along with their issues and opportunities. Dr. KSS is a paid contributor to Stock Gumshoe, he has agreed to our trading restrictions but he chooses his own topics and his words and opinions are his own.

Author Archives

  • The 12 Biotechs of Christmas: Six

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Let’s turn our attention today, in a mild […]

  • The 12 Biotechs of Christmas: Five

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Our fifth stock on this Christmas outing is […]

  • The 12 Biotechs of Christmas: Four

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] It’s a warm Sunday afternoon a few months […]

  • The Twelve Biotechs of Christmas: Two

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] After the New Year, we plan to look […]

  • Such A Pleasant Stay

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “Thanks to you I’m much obliged Such a […]

  • Sea of Tranquility

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] “I live in the light of the bright summer […]

  • Tropic of Palatin

    [Ed. Note: Dr. KSS writes about biotech and medicine for the Irregulars. He has agreed to our trading restrictions, chooses his own topics and his thoughts and opinions are his own. His previous columns and recent comments can be found on his Stock Gumshoe page.] “He had never seen her body so abandoned, so unconscious […]

  • Ten Common Biotech Investing Mistakes

    [Ed. Note: Dr. KSS writes about medicine biotech stocks for the Gumshoe Irregulars. He chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page for his past articles and most recent comments.] Assessing biotechnology stocks involves use of lots of mental microscopes and magnifying lenses. But the task […]

  • Quickster: T2 Biosystems ($TTOO)

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. Visit his Stock Gumshoe page to see his biography, latest comments and past articles.] About 18 months ago, I came across tiny Boston-area diagnostics start-up […]

  • The State of Things: Ruction at Regulus

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and recent comments here.] The State of Things is a classy 1982 Wim Wenders film in which a film […]

  • Conflict Diamonds

    [Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trade restrictions, chooses his own topics, and his words and opinions are his own. You can see all his past articles and more recent comments here.] Picture the gurbling fumaroles of Yellowstone: from the late 1990’s and on into […]

  • The Bedlam in Young Goliath

    [Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, choses his own topics, and his words and opinions are his own. All of his previous articles and most recent comments can be found on his Stock Gumshoe page.] “I have seen you shake And […]

  • Recent Author Comments

    On The Twelve Biotechs of Christmas: One
    Somebody needs to get the great JimT47 on the horn, get him to pull up the structure of 253 (I have a drawing) and see what he thinks about solubility prospects.[...]
    On The Twelve Biotechs of Christmas: One
    OK, a little comic relief in order. A man with an 18.9-inch flaccid penis in Mexico is refusing doctor recommendations that it be surgically reduced in size to make life, um, easier for him. Apparently, these are NOT alternative facts. http://www.comple[...]
    On The Twelve Biotechs of Christmas: One
    I think cool heads need to prevail here. The more times I re-read the blurbage from today the more confused I am by their true motives, but as of yet I do not deem them untrustworthy. These people are smart enough to know that the belle of the ball is 253,[...]
    On The Twelve Biotechs of Christmas: One
    Certainly not a good way to begin a week. One wishes they'd be clearer about the nature of the newer issue with what was the lead drug. The second agent is NOT a replacement for that, not a substitute....it's working by a different mechanism and leaves som[...]
    On The Twelve Biotechs of Christmas: One
    OT: I spent a couple of hours just now looking over legal accounts, briefs and reporting regarding this case. It is impressive (right word?) how such tooth and claw fighting is devoted to every word in every phrase in this litigation. I don't say the diffr[...]
    On The Twelve Biotechs of Christmas: One
    Hi Mark: Will answer comprehensively later on tonight.[...]
    On The Twelve Biotechs of Christmas: One
    OT: I also think there will be changes. Let me mull that one a bit. I need to run to a Brahms performance on campus and will post later on this evening.[...]
    On The Twelve Biotechs of Christmas: One
    Thanks Phil. Please note that in my view, one person's opinion, Ardelyx is not a bad stock to be in. I have no position now, but might take one as PDUFA draws near this summer. Already I am sure some angry person somewhere will grill me for being inconsist[...]
    On The Twelve Biotechs of Christmas: One
    Disquieting. I can't recall: is the threshold for insidership 5 or 10 percent ownership? An odd time to sell: on the finish line, as it were. Do they know something as insiders, do they suspect something, or do they need funds elsewhere in the portfolio? I[...]
    On The Twelve Biotechs of Christmas: One
    I meant, what I intended to say, was that I would just lay low yesterday and today to work on columns, which I've done. I admit I love the threads, the boisterous agora, and have a pretty hard time staying away too. This casbah is always rocking. It common[...]
    On The Twelve Biotechs of Christmas: One
    I love $CAPR but increasingly question its merit as an investment. It seems to be more oriented to outstanding research rather than bringing a program definitely in for landing and getting it off to the FDA. I am still long, but beginning to consider other[...]
    On The Twelve Biotechs of Christmas: One
    Glenn and I had to cancel a recent planned discussion with Terry Norchi. Probably time for us to try rescheduling that....it was my fault we couldn't do it.[...]
    On The Twelve Biotechs of Christmas: One
    My suggestion is that we keep all discussion of stocks of common interest on the thread. That's the object of the exercise. Cleveland's posts are of great moment, valuable to all, and I'd prefer to see them in the forum. This is becoming a powerful forum, [...]
    On The Twelve Biotechs of Christmas: One
    A good question and I am glad you are snooping around into things. I don't have an answer at all. I tend to think that because the drug showed an effect at 2 of 3 data points that the effect is real. Keep in mind much hasn't been disclosed about the nature[...]
    On The Twelve Biotechs of Christmas: One
    A painting of Robert Califf given to the Duke Clinical Research Institute. https://pbs.twimg.com/media/C2nZw6BXcAAOIMt.jpg Remind you of anyone?[...]
    On The Twelve Biotechs of Christmas: One
    Bristol has abandoned plans to study nivolumab and Yervoy in lung cancer. But is not saying why so as "to protect the integrity of other trials with the agents." Whoa Bessie.....shouldn't that be the other way around? Oughtn't you to be forthcoming so that[...]
    On The Twelve Biotechs of Christmas: One
    Hi, sure: just email me at lynn@stockgumshoe.com. Glad to help.[...]
    On The Twelve Biotechs of Christmas: One
    I can't recall if I've told the story of my 21-Flush Salute patient. I had a long term CIC'er in the hospital for another reason, and days went by with appropriate laxative use but without a result. The nurse told me on evening rounds he was pretty uncomfo[...]
    On The Twelve Biotechs of Christmas: One
    Watch out Ben. If you keep evincing expertise in the colon, we'll have to nickname you "Stooly." Stooly Jam does have a je ne sais quois about it.[...]
    On The Twelve Biotechs of Christmas: One
    Yes, definitely. Cheap and effective, especially if you just use enough and stay ahead of the problem. For really bad problematic CIC'ers, sometimes seems no drug works, and plecanatide is not blasting powder. People with real dyed-in-the-wool CIC I someti[...]

    This site and Stock Gumshoe publications and authors do not offer individual financial, investment, medical or other advice. Nothing on this site should ever be considered to be personal advice, research or an invitation to buy or sell any securities. We also make mistakes and bad decisions sometimes, and our reasoning or data should be checked against trusted sources before they inform your investing decisions. Choices regarding how to invest your money or otherwise manage your life or finances are yours, we share only our analysis and opinion and all authors or commenters are individually responsible for the words and opinions they share here. Please read our important disclaimers and policies. Stock Gumshoe is supported by subscribers and by sponsors and advertisers. Stock Gumshoe's employee authors will disclose holdings in any stock covered at time of publication and will not trade in any stocks written about for at least three days after publication. Please see below for complete disclosure, disclaimer and policy information.